Among disparate views, scales tipped by the ethics of system integrity.

Abstract

The Controlled Substance Act of 1970 designates drugs into one of five schedules, based upon medicinal value, harmfulness, and potential for abuse and addiction [1]. Schedule I drugs are those considered to have a high potential for abuse with no medicinal value, Schedule II drugs have a high potential for abuse with medicinal value, Schedule III designates drugs that have a lower potential for abuse than Schedule I and II drugs, Schedule IV drugs have a low potential for abuse, and Schedule V drugs are thought to have an abuse potential even lower than those designated as Schedule IV. A controversial decision by the US Food and Drug Administration (FDA) in 1971 permitted hydrocodone to have a split Schedule, with pure hydrocodone designated as a Schedule II drug and hydrocodone combined with acetaminophen designated as Schedule III [2]. However, at present, hydrocodone is not sold commercially in the United States in its pure form, but rather always in combination with another medication.

DOI: 10.1111/pme.12257_4

Cite this paper

@article{Schatman2013AmongDV, title={Among disparate views, scales tipped by the ethics of system integrity.}, author={Michael E. Schatman and Beth D Darnall}, journal={Pain medicine}, year={2013}, volume={14 11}, pages={1629-30} }